Anixa promotes CFO/COO Michael Catelani to President; salary $434,512

Anixa Biosciences Inc

Michael Catelani promoted to President effective April 14, 2022; retains roles as COO and CFO.
Annual base salary increased to $434,512; granted option to purchase 100,000 shares at closing price.
Stock option vests over 36 months, ten-year term, cashless exercise permitted.
Dr. Amit Kumar steps down as President but remains Chairman and CEO; no related-party transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael Catelani

President

ANIX · Anixa Biosciences Inc

Effective: 2022-04-14
Filed: April 15, 2022, 7:59 PM ET

On April 14, 2022, the Board of Directors of Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) promoted Michael Catelani, the current Chief Operating Officer and Chief Financial Officer of the Company, to President of the Company effective immediately.

Role change

Amit Kumar

President

ANIX · Anixa Biosciences Inc

Effective: 2022-04-14
Successor: Michael Catelani
Filed: April 15, 2022, 7:59 PM ET

Mr. Catelani is replacing Dr. Amit Kumar, the prior President and current Chairman and Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Catelani changed role as President at Anixa Biosciences Inc.

Action: promoted
Role: President

Exact text from the filing

On April 14, 2022, the Board of Directors of Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) promoted Michael Catelani, the current Chief Operating Officer and Chief Financial Officer of the Company, to President of the Company effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Amit Kumar changed role as President at Anixa Biosciences Inc.

Action: replaced
Role: President

Exact text from the filing

Mr. Catelani is replacing Dr. Amit Kumar, the prior President and current Chairman and Chief Executive Officer of the Company.

View on SEC.gov

Anixa Biosciences Inc filing history →

Source: SEC EDGAR

accession 0001493152-22-010016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.